Scalper1 News
Contract research organization Charles River Laboratories (CRL) said Thursday that it’s agreed to buy the CRO business of Belgian drugmaker Galapagos NV. Charles River stock touched a more than five-year high in early trading on the stock market today. Charles River will pay $179 million in cash upfront, plus up to $7 million in “future performance payments.” The acquisition includes Galapagos units Argenta and BioFocus, whose “in vitro Scalper1 News
Scalper1 News